Table 2.

Results of Question 4 and comparison with the previous survey. In italics underlined: p = 0.0004, otherwise p > 0.05.

Question 4		Current survey (n = 596)	Previous survey (n = 383)
Concerning biosimilars, you worry (it is possible to choose more than one option):	(a) That the molecular basis of the biosimilar is different from that of the reference drug	206 (34.6%)	126 (32.9%)
	(b) About safety profile (mainly infections and cancers)	274 (46.0%)	178 (46.5%)
	(c) About tolerability	182 (30.5%)	122 (31.9%)
	(d) That the biosimilar could be less effective than the reference drug	299 (50.2%)	148 (38.6%)
	(e) You have no specific concerns about biosimilars	131 (22.0%)	101 (26.4%)